New Haven, CT – [Insert Date] – Biohaven Pharmaceuticals has announced a significant pause in the pivotal clinical trials for its promising epilepsy candidate, opakalim (BHV-7000), following a partial clinical hold issued by the U.S. Food and Drug Administration (FDA). The regulatory agency’s decision stems from safety signals identified during nonclinical testing, specifically concerning a metabolite of opakalim. This development introduces a new layer of uncertainty for the drug’s journey towards market approval, particularly as it navigates a competitive landscape for focal onset seizures.
The FDA’s intervention means that new patient enrollment in the ongoing pivotal studies evaluating opakalim for focal epilepsy will be temporarily halted. This decision underscores the FDA’s commitment to rigorous safety assessments and its proactive approach to potential risks in drug development. While existing patients in the trials can continue to receive treatment, the pause in new participant recruitment is a critical setback for Biohaven and its ambitious timeline.
Opakalim’s Development and the Emergence of Safety Concerns
Opakalim is a novel, selective opener of voltage-gated potassium channels, specifically Kv7.2 and 7.3. These channels play a crucial role in regulating neuronal excitability within the nervous system, making them a key target for anti-seizure therapies. The drug was initially being evaluated in pivotal trials, RISE-2 (NCT06132893) and RISE-3 (NCT06309966), alongside an open-label extension study (NCT06443463), with the aim of securing regulatory approval for the treatment of focal onset seizures.
The current disruption arose when Biohaven, in its communications with global regulatory bodies, including the FDA, disclosed findings from its comprehensive nonclinical testing. These studies, which involved rodent models, identified a specific metabolite of opakalim. While the exact nature and potential risks of this metabolite have not been fully elucidated, Biohaven reported to regulators that there was "insufficient information" regarding its potential risk to humans. This acknowledgment triggered the FDA’s review and subsequent decision to impose a partial clinical hold.
A Chronology of Events Leading to the Clinical Hold
The sequence of events highlights the swift regulatory response to emerging safety data:
- Recent Nonclinical Testing: Biohaven conducted comprehensive nonclinical studies, including metabolite characterization, as part of its ongoing drug development program for opakalim.
- Identification of a Metabolite: During these nonclinical assessments, a specific metabolite of opakalim was identified.
- Safety Signal Identified: Preliminary analysis of the nonclinical data indicated potential safety concerns associated with this metabolite, prompting Biohaven to proactively engage with regulatory authorities.
- Disclosure to Regulators: Biohaven formally communicated its findings and concerns regarding the metabolite’s safety profile to global regulators, including the FDA. The company stated that there was "insufficient information" to fully assess the risk to humans.
- FDA Review and Partial Clinical Hold: Following the disclosure, the FDA conducted its own review of the submitted data. Based on its assessment, the agency issued a partial clinical hold on the pivotal trials.
- Enrollment Paused: The FDA’s directive explicitly instructs Biohaven to pause new patient enrollment in the opakalim program until conclusive nonclinical data on the metabolite’s safety is generated and reviewed.
- Existing Patients Continue Treatment: Crucially, the partial clinical hold permits Biohaven to continue dosing existing patients who are already participating in the RISE-2, RISE-3, and open-label extension studies.
Impact on Clinical Trials and Timeline
The partial clinical hold primarily affects the RISE-2 trial. This study, designed to evaluate opakalim in adult patients with focal onset seizures, is still actively enrolling patients. The pause in recruitment will undoubtedly delay the trial’s progression and the generation of further data.
In contrast, the RISE-3 trial, another pivotal study for opakalim in focal epilepsy, has already reached full enrollment and randomized all its participants. Therefore, the partial clinical hold is not expected to significantly impact the timeline for RISE-3. Biohaven has previously indicated that it anticipates a data readout for RISE-3 in the second half of 2026. This suggests that the company may be able to proceed with the analysis and reporting of data from RISE-3 without substantial delays, provided no new issues arise.
The open-label extension study allows participants from the pivotal trials to continue receiving opakalim after completing their primary study period. The continuation of this study for existing patients is vital for long-term safety monitoring and for providing patients with continued access to a potential treatment.
Supporting Data and Context: The Market for Focal Epilepsy Therapies
The focal epilepsy market is a significant and growing area within the pharmaceutical industry. GlobalData, the parent company of Clinical Trials Arena, forecasts this market to be worth a substantial $17.8 billion by 2035 across the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan). This projected growth underscores the unmet need for effective and safe treatment options for the millions of individuals living with focal onset seizures.
Opakalim’s mechanism of action, targeting Kv7.2 and 7.3 potassium channels, represents a potentially novel approach to seizure control. This pathway is understood to play a critical role in modulating neuronal excitability, and successful modulation could lead to a significant reduction in seizure frequency and severity.
A Competitive Landscape: Azetukalner and Opakalim’s Race
The development of opakalim is taking place within a competitive landscape. Xenon Pharmaceuticals is also progressing its own drug candidate, azetukalner, which utilizes a similar mechanism of action targeting Kv7 channels for the treatment of focal epilepsy. Xenon has achieved late-stage success with azetukalner and plans to submit a New Drug Application (NDA) to the FDA in the third quarter of 2026. This timeline suggests that azetukalner could potentially be the first therapy from this specific drug class to gain market approval.
While there are already a range of anti-seizure medications available, the introduction of novel mechanisms of action like those offered by opakalim and azetukalner holds the promise of providing improved efficacy, better tolerability, or different treatment profiles for patients who may not respond adequately to existing therapies.
Recent Licensing Deal and Previous Setbacks
The current clinical hold comes on the heels of a significant licensing deal for opakalim. Just days prior to the FDA’s announcement, SK Biopharmaceuticals acquired the global rights to opakalim from Biohaven for an upfront payment of $350 million. According to Biohaven, SK Biopharmaceuticals was granted access to all clinical and nonclinical data, including the metabolite characterization studies, prior to the agreement’s finalization. This raises questions about the timing of the safety signal discovery relative to the deal’s execution and whether SK Biopharmaceuticals was fully aware of the potential risks.
This developmental pause marks another hurdle for opakalim. The drug has previously encountered setbacks in its development for other neurological conditions. In 2025, opakalim failed to demonstrate efficacy in pivotal studies for bipolar disorder and major depressive disorder (MDD). These previous failures, combined with the current clinical hold, add to the challenges opakalim faces in its quest for regulatory approval.
Official Responses and the Path Forward
Biohaven has formally communicated its interactions with global regulators via an 8-K filing, providing transparency regarding the situation. The company stated that the FDA’s decision was based on "insufficient information" regarding the risk of a specific opakalim metabolite identified in nonclinical rodent-based testing.
While the partial clinical hold is a significant development, Biohaven’s ability to continue dosing existing patients in its trials is a crucial aspect. This allows for the collection of valuable long-term safety data and ensures that patients currently benefiting from the investigational treatment are not abruptly discontinued.
The immediate focus for Biohaven will be on generating conclusive nonclinical data to address the FDA’s concerns about the opakalim metabolite. This will likely involve further in-depth studies to characterize the metabolite, understand its pharmacokinetic and pharmacodynamic properties, and rigorously assess its potential toxicity in relevant preclinical models. The company will then need to present these findings to the FDA for review, with the expectation of securing the lifting of the partial clinical hold.
The implications of this hold extend beyond the immediate trial progress. It raises questions about the broader safety profile of opakalim and its long-term implications. Furthermore, the significant upfront payment from SK Biopharmaceuticals in the recent licensing deal now carries an added layer of risk for the acquiring company, pending the resolution of the FDA’s concerns. The industry will be closely watching Biohaven’s efforts to navigate this challenge and to provide the necessary data to assure regulators of opakalim’s safety. The ultimate success of opakalim, and indeed the future of the Kv7 channel opener class in focal epilepsy, may hinge on the company’s ability to definitively address the safety signals surrounding this newly identified metabolite.
About the Author
